The conglomerate business model has been good for fiser. It was good for all these other companies you don't know, v artists, m big drug makers that have dig consumer divisions and a glaso as well. And the reason that they're doing it is because you make a lot more money off of drugs than you do off consumer products. Belly looked at the way that astro senika went heavily into a no do drugg research m a, particularly in the cancer field. I i hapven to be here. Im all setting them now. I have to go.
Dr. Ian Lustbader, Clinical Professor of Medicine at NYU Langone, discusses why the shot-or-test rule makes sense. Bloomberg Businessweek Editor Joel Weber and Bloomberg News U.S. Health Care Reporter Cynthia Koons explain why Covid pills may save lives, but they won’t end the pandemic. Bloomberg News Health Editor John Lauerman talks about Johnson & Johnson's plan to split off its consumer division, following in the footsteps of other big drugmakers that have moved to focus on the more-profitable pharmaceutical market. Kathy Kraninger, VP of Regulatory Affairs at Solidus Labs, shares her thoughts on crypto manipulation and regulation. And We Drive to the Close with Bill Smead, CIO at Smead Capital Management.
Hosts: Carol Massar and Tim Stenovec. Producer: Paul Brennan.
See omnystudio.com/listener for privacy information.